Promising drug for rare fat disorder trial halted early

NCT ID NCT05088460

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 22 times

Summary

This study tested a drug called REGN4461 in people with familial partial lipodystrophy, a rare condition where fat is distributed abnormally, leading to serious metabolic issues like high triglycerides and diabetes. The trial aimed to see if the drug could improve blood fat and sugar levels. It was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo

    Santiago de Compostela, Galicia, 15706, Spain

  • Ege University Faculty of Medicine

    Izmir, Bornova, 35100, Turkey (Türkiye)

  • Excel Medical Clinical Trials - A Flourish Research Site

    Boca Raton, Florida, 33434, United States

  • ICAN, Institute of Cardiometabolism and Nutrition

    Paris, 75013, France

  • National Institute of Health

    Bethesda, Maryland, 20892, United States

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

Conditions

Explore the condition pages connected to this study.